SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Gufic Biosciences - Quaterly Results

13 Aug 2025 Evaluate
The company witnessed a 11.88% growth in the revenue at Rs. 2269.12 millions for the quarter ended June 2025 as compared to Rs. 2028.12 millions during the year-ago period.Net Profit of the company move down -42.13% to Rs. 120.72  millions from Rs. 208.59 millions  in the same quarter last year.A decline of 332.29 millions was observed in the OP in the quarter ended June 2025 from 370.37 millions on QoQ basis.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 2269.12 2028.12 11.88 2269.12 2028.12 11.88 8198.06 8066.66 1.63
Other Income 8.94 12.55 -28.76 8.94 12.55 -28.76 36.15 21.77 66.05
PBIDT 332.29 370.37 -10.28 332.29 370.37 -10.28 1386.03 1480.48 -6.38
Interest 92.34 46.24 99.70 92.34 46.24 99.70 231.12 153.60 50.47
PBDT 239.95 324.13 -25.97 239.95 324.13 -25.97 1154.91 1326.88 -12.96
Depreciation 77.19 43.05 79.30 77.19 43.05 79.30 210.64 170.17 23.78
PBT 162.76 281.08 -42.09 162.76 281.08 -42.09 944.27 1156.71 -18.37
TAX 42.04 72.49 -42.01 42.04 72.49 -42.01 244.95 295.36 -17.07
Deferred Tax 19.84 2.49 696.79 19.84 2.49 696.79 57.51 31.65 81.71
PAT 120.72 208.59 -42.13 120.72 208.59 -42.13 699.32 861.35 -18.81
Equity 100.28 100.28 0.00 100.28 100.28 0.00 100.28 100.28 0.00
PBIDTM(%) 14.64 18.26 -19.81 14.64 18.26 -19.81 16.91 18.35 -7.88

Gufic Biosciences Share Price

293.00 5.90 (2.06%)
06-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1850.40
Dr. Reddys Lab 1310.50
Cipla 1365.25
Zydus Lifesciences 939.10
Lupin 2442.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×